Unlocking precision: the revolutionary impact of ⁶⁸Ga-PSMA PET/CT in prostate cancer care
In the realm of medical diagnostics, the groundbreaking procedure of 68Ga-PSMA PET/CT has emerged as a game-changer, offering unprecedented insights into the assessment and management of prostate cancer. Its extraordinary precision enables clinicians to visualize prostate cancer at a molecular level. It has revolutionized the diagnosis, staging, and personalized treatment strategies for prostate cancer, ultimately enhancing patient outcomes and reshaping the landscape of prostate cancer care. Below is the review of just some of the latest studies.
Bone scans prove to be less accurate in the initial staging of prostate cancer, often providing overstated results. A recent comparative multicenter study between bone scans and PSMA PET with 167 patients revealed that a staggering 57% of positive bone scans were, in fact, false positives. This indicates that a significant portion of patients identified as having low-volume metastatic disease by bone scans may, in reality, have localized disease. This obviously has implications for the therapeutic decision making but may also negatively impact the psychological well-being of the patients.
A further study aimed to evaluate the additional prognostic value of presurgical PSMA-PET for predicting biochemical recurrence (BCR). In patients with high-risk prostate cancer, using PSMA-PET before surgery indeed helps predict the risk of cancer recurrence more accurately than the existing risk assessment scores CAPRA or postsurgical CAPRA-S. The findings indicate that presurgical PSMA-PET is a valuable tool for better understanding the risk of cancer returning after surgery in these patients.
Yet another study suggests that evaluating tumor-to-salivary gland ratio (PSG score) with the help of 68Ga-PSMA PET can help predict how patients with mCRPC will respond to the 177Lu-PSMA therapy. The higher was the score, the better turned out to be the outcomes of the treatment. Higher PSG scores correlated with stronger PSA decline, longer progression-free and overall survival.
68Ga-FAPI PET/CT for solid tumors like breast, colon and pancreatic carcinomas.
Don’t settle for anything less than the utmost excellence.
Die Zukunft hat begonnen. Therapie auf dem nächsten Level.
The future has started. Experience therapy on the next level.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. The cookies categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. Read our full Cookie Policy.